Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
01 2020
Historique:
received: 13 04 2019
accepted: 13 06 2019
pubmed: 16 8 2019
medline: 6 8 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

This FranceCoag network study assessed 33 patients with congenital factor XIII (FXIII) deficiency presenting FXIII levels <10 iu/dl. Diagnosis was based on abnormal bleeding in 29 patients, a positive family history in 2, recurrent miscarriages in 1 and was fortuitous in 1. Eighteen patients (62·1%) presented life-threatening umbilical or intracranial haemorrhages (ICH). Seven of the 15 patients who experienced ICH were diagnosed but untreated, including 3 with secondary neurological sequelae. All pregnancies without prophylaxis (26/26) led to miscarriages versus 3/16 with prophylaxis. In patients exhibiting FXIII levels <10 iu/dl, prophylaxis could be discussed at diagnosis and at pregnancy. Further controlled prospective studies are needed.

Identifiants

pubmed: 31414482
doi: 10.1111/bjh.16133
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-320

Informations de copyright

© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Références

Doncarli, A., Demiguel, V., Guseva Canu, I., Goulet, V., Bayart, S., Calvez, T., Castet, S., Dalibard, V., Demay, Y., Frotscher, B., Goudemand, J., Lambert, T., Milien, V., Oudot, C., Sannié, T., Chambost, H. & FranceCoag Network (2019) FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders. European Journal of Epidemiology, 34, 521-532.
Dorgalaleh, A. & Rashidpanah, J. (2016) Blood coagulation factor XIII and factor XIII deficiency. Blood Reviews, 30, 461-475.
Dorgalaleh, A., Tabibian, S.H., Safa, M., Shams, M. & Naderi, M. (2017) Minimal factor XIII activity level to prevent major spontaneous bleeds: comment. Journal of Thrombosis and Haemostasis, 15, 2279-2280.
Hsieh, L. & Nugent, D. (2008) Factor XIII deficiency. Haemophilia, 14, 1190-1200.
Menegatti, M. & Peyvandi, F. (2019) Treatment of rare factor deficiencies other than hemophilia. Blood, 133, 415-424.
Menegatti, M., Palla, R., Boscarino, M., Bucciarelli, P., Muszbek, L., Katona, E., Makris, M., Peyvandi, F. & PRO-RBDD Study Group. (2017) Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis, 15, 1728-1736.
Mumford, A.D., Ackroyd, S., Alikhan, R., Bowles, L., Chowdary, P., Grainger, J., Mainwaring, J., Mathias, M. & O'Connell, N. (2014) Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. British Journal of Haematology, 167, 304-326.
Muszbek, L., Bagoly, Z., Cairo, A. & Peyvandi, F. (2011) Novel aspects of factor XIII deficiency. Current Opinion in Hematology, 18, 366-372.
Odame, J.E., Chan, A.K., Wu, J.K. & Breakey, V.R. (2014) Factor XIII deficiency management: a review of the literature. Blood Coagulation & Fibrinolysis, 25, 199-205.

Auteurs

Séverine Bouttefroy (S)

Hospices Civils de Lyon - Unite d'Hemostase Clinique, Hôpital Cardiologique Louis Pradel, Lyon, France.

Sandrine Meunier (S)

Hospices Civils de Lyon - Unite d'Hemostase Clinique, Hôpital Cardiologique Louis Pradel, Lyon, France.

Vanessa Milien (V)

AP-HM, FranceCoag, Marseille, France.

Mohamed Boucekine (M)

AP-HM, FranceCoag, Marseille, France.

Pierre Chamouni (P)

Hemophilia Care Center, Rouen University Hospital, Rouen, France.

Dominique Desprez (D)

Haemophilia Treatment Centre, Strasbourg University Regional Hospital, Strasbourg, France.

Annie Harroche (A)

Haemophilia Treatment Centre, APHP, Hospital Necker, Paris, France.

Audrey Hochart (A)

Haematology and Transfusion, CHU Lille, Hospital Necker, Lille, France.

Marie Françoise Thiercelin-Legrand (MF)

Haemophilia Treatment Centre, University Hospital of Toulouse, Toulouse, France.

Bénédicte Wibaut (B)

Haematology and Transfusion, CHU Lille, Hospital Necker, Lille, France.

Hervé Chambost (H)

AP-HM, FranceCoag, Marseille, France.
Hemophilia Care Center, La Timone Hospital and Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France.

Lucia Rugeri (L)

Hospices Civils de Lyon - Unite d'Hemostase Clinique, Hôpital Cardiologique Louis Pradel, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH